According to recent reports, fast engraftment with minimal transplant-related toxicity and mortality (TRT, TRM) can be achieved by using reduced-intensity preparative regimens in allogeneic hematopoietic stem cell transplantation (HSCT). We report our experience with related (39%) and unrelated (61%) HSCT in 44 high risk patients (AML, ALL, CML, CLL) receiving either busulfan/fludarabine or busulfane/fludarabine/ATG or TBI/fludarabine as reduced-intensity preparative regimens. Organ toxicity was minimal with mild mucositis and no major bleeding. Acute GVHD was recorded in 64% of the patients. Twenty-three patients achieved complete remission after transplantation, and complete chimerism was obtained in all patients with stable engraftment (35 patients). Twenty-nine patients died: 15 due to relapse/progression, 14 due to TRM. Survival with median follow-up of 18.5 months was significantly better in patients with matched related transplants compared to patients with other transplants. However, there was no difference between related and unrelated transplants with regard to engraftment, TRM and GVHD. In conclusion, our results in high-risk patients transplanted in CR or with smoldering leukemia from a related donor are encouraging, although a longer follow-up and a larger group of patients is needed in order to evaluate the role of different reduced-intensity preparative regimens in unrelated and related HSCT. Bone Marrow Transplantation (2002) 30, 651-659. doi:10.1038/sj.bmt.1703697 Keywords: reduced conditioning regimen; AML; ALL; CML; GVHD Preparative regimens of reduced intensity are being increasingly evaluated in patients who have hematological malignancies not suitable for conventional myeloablative conditioning due to poor performance status, advanced age or comorbidity. This approach has been shown to induce miniCorrespondence: N Basara, Clinic for Bone Marrow Transplantation and Hematology/Oncology,
mal procedure-related toxicity [1] [2] [3] and to facilitate fast donor cell engraftment, development of donor chimerism 4, 5 and generation of graft-versus-leukemia effects. 6, 7 Although toxicity is reduced, deaths due to acute and chronic GVHD, as well as infections are observed. There are many preparative regimens 6, 7 and most of the reduced-intensity preparative regimens are fludarabine-based conditioning regimens combined with busulfan, 2, 8 cyclophosphamide, 3, 6, 9 melphalan 1, 5 or total body irradiation. 10, 11 In order to obtain more insight into the feasibility of different preparative regimens we performed allogeneic HSCT randomly using three different fludarabine-based preparative regimens in a group of 44 patients with hematological malignancies not suitable for conventional preparative regimens. These were low-dose busulfan in combination with fludarabine and anti-thymocyte-globulin (Bu/Flu/ATG), Bu/Flu without ATG and 4 Gy total body irradiation in combination with fludarabine (TBI/Flu).
Patients and methods
Between February 1999 and December 2000, 44 patients who had an HLA-matched or mismatched related or unrelated donor as determined by serological typing for HLA-A/B and molecular typing for HLA-DR/DQ, were treated in our center. The most important patient characteristics are depicted in Table 1 . Twenty-three were male and 21 female. The age range at the time of transplantation was 20 to 67 years, with a median of 52 years. Twenty-seven patients had AML, five ALL, nine CML and three CLL. Patients with hematological malignancies were included in this study if they were older than 55 years. They were also eligible if they were younger than 55, but were poor candidates for conventional myeloablative therapy because of concurrent medical conditions (cardiac ejection fraction less than 60%, lung function tests less than 60% predicted, abnormal liver function, poor performance status, or extensive prior chemotherapy including autologous transplant). Patients older than 55 years of age (n = 17), those with a previous failed autologous transplant (n = 4), refractory disease and/or organ dysfunction (n = 10), severe infection (n = 7) and other reasons such as treatment within a phase III study for CLL (multicentre German study) 12 and CML patients (n = 5) (multicenter German study) were included. Patients with graft failure after a first transplant receiving CsA AML = acute myeloid leukemia; CML = chronic myeloid leukemia; sAML = secondary AML; biphen = biphenotypic; prec = precursor; CLL = chronic lymphoblastic leukemia; ALL = acute lymphoblastic leukemia; CR = complete remission; CP = chronic phase; PBSC = peripheral blood stem cells; BM = bone marrow; MRD = matched related donor; MUD = matched unrelated donor; PMRD = partially matched related donor; CsA = cyclosporine A; Pred = prednisolone; MTX = methotrexate; MMF = mycophenolate mofetil.
a dose-reduced preparative regimen before the second transplant were not included in this study. Patients were randomly assigned to one of the three preparative regimens, except for those treated within multicenter clinical trials. Informed consent was obtained from each patient and donor before initiation of the protocol. Bu/Flu/ATG given to 10 patients, consisted of intravenous fludarabine 30 mg/m 2 over 30 min on days Ϫ6 to Ϫ2, oral busulfan (4 mg/kg/day) for 2 consecutive days (Ϫ6 and Ϫ5) and ATG (Fresenius) at 2.5 mg/kg/day for 4 consecutive days; 13 four of these patients (three with CLL and one with AML) received ATG (Fresenius) at a dose of 10 mg/kg/day as already published. 2 The Bu/Flu preparative regimen was used in 18 patients and was the same as the above-mentioned Bu/Flu, but without ATG. The TBI/Flu preparative regimen consisted of 2 Gy/day irradiation on 2 consecutive days delivered laterally as two doses at a high-dose rate, followed by fludarabine (30 mg/m 2 over 30 min on days Ϫ6 to Ϫ2) and was given to 16 patients. Thirty-three patients received unmanipulated PBSC from their HLA-identical sibling (15) or from a matched unrelated donor (18) , respectively. Six patients received unmanipulated PBSC from related (one) or unrelated mismatched (five) donors. Five patients received bone marrow from HLA-mismatched related (one), HLAmatched unrelated (two) or HLA-mismatched unrelated donors (two).
Hematopoietic stem cell collection
Sibling and unrelated stem cell donors received granulocyte colony-stimulating factor (G-CSF) at 10 g/kg subcutaneously daily in two split doses, as already described, 14 on days Ϫ4 to 0. PBSCs were collected by a single largevolume apheresis (4 ϫ blood volume, not longer than 5 h) on day Ϯ0 using a Cobe Spectra. Marrow (BM) was collected on day Ϯ0 under general anesthesia using conventional techniques. 
Supportive care
Patients were treated in single HEPA airflow rooms. All patients received prophylaxis with cotrimoxazole from day +30 after transplant, at a dose of one double-strength tablet twice daily twice weekly, or pentamidine in case of poor graft function, monthly against Pneumocystis carinii infection. Acyclovir prophylaxis was administered orally at a dose of 400 mg four times per day starting from day 0 to day +14. Itraconazole prophylaxis was employed from day Ϫ7 as a 2 ϫ 10 ml suspension, until patients received immunosuppression. Antibacterial prophylaxis was not used. Episodes of febrile neutropenia were treated with broad spectrum antibiotics with the subsequent addition of amphotericin B, if a fungal infection was suspected. All patients received only CMV-negative blood products in order to maintain Hb levels above 8 g/dl and platelet counts above 10 ϫ 10 9 /l.
Chimerism analysis
Chimerism analysis was performed as already described. 13 Mixed chimerism after HSCT was monitored quantitatively using a PCR-short tandem repeat loci system. 15 Briefly, DNA was extracted from the buffy coat from 10 ml of EDTA-containing peripheral blood, using the QIAamp Blood Kit (Quiagen, Hilden, Germany). PCR amplification was performed in a 9600 DNA thermal cycle system (Perkin Elmer, Foster City, CA, USA) using 100-500 ng of genomic DNA, 5-10 pmol of each primer and 0.5 units of polymerase (Appligene-Oncor, Illkirch, France). PCR products were analyzed together with an internal standard in the same lane of a standard 6% polyacrylamide denaturing sequencing gel.
CMV Screening
Patients were checked systematically twice per week for CMV infection by CMV-PCR and by antigenemia assay. In a positive specimen, results are reported as viral load
Bone Marrow Transplantation and as number of antigen positive cells and the patient was considered positive when at least two infected cells out of 2 ϫ 10 5 leukocytes were present. Thirty-three (75%) donor-recipient pairs were CMV seropositive prior to transplantation.
GVHD prophylaxis and grading
GVHD prophylaxis consisted of cyclosporine A (CsA) alone (5 g/kg) starting on day Ϫ1 in 22 patients. In 17 patients, GVHD prophylaxis consisted of CsA, and MMF at a dose of 2 g daily, in divided doses, orally. Five patients received CsA and MTX at a dose of 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3 and +6. Intravenous CsA was switched to the p.o. formulation as soon as patients were able to tolerate medication p.o. and was continued for up to 6 months. Patients who survived 100 days or longer were monitored for chronic GVHD. Acute and chronic GVHD were graded according to the consensus criteria. 16, 17 Patients had regular follow-ups at monthly intervals post transplant to assess disease response and remission status.
Toxicity grading
Non-hematologic organ dysfunction from day 0 to day +28 was considered as transplant-related toxicity (TRT) and graded according to the criteria of Bearman et al. 18 
Statistical evaluation
We used the SPSS software to perform all statistical tests. Actuarial overall and event-free survivals were calculated on 2 May 2002 from the day of transplantation, according to the methods of Kaplan and Meier. Significance of differences between the curves was estimated by the log-rank test. For subgroup analysis with regard to preparative regimen, we used the t-test and Mann-Whitney U test. The median patient follow-up (ie those surviving day 50) was 18.5 months. The analysis was performed in patients with follow-ups of at least 4 months.
Results

Toxicity
The conditioning regimens were generally well tolerated. Transplant-related organ toxicity was moderate in these previously heavily treated patients (Figure 1a ). There was no significant difference in toxicity with regard to the three different preparative regimens. During the first dose of ATG, most patients (10 of 11) experienced fever and moderate hypotension. The use of MTX in GVHD prophylaxis resulted in severe mucositis. We did not observe any patients experiencing veno-occlusive disease. According to the Bearman scale, 18 seven patients experienced Ͼgrade II toxicity (Table 2) . One patient developed grade III pulmonary toxicity; one developed grade III renal toxicity due to E. coli sepsis; two patients developed grade III mucositis; one developed grade III heart toxicity and required a pacemaker 40 days after PBSCT and one developed grade III Bone Marrow Transplantation 
Table 2
Transplantation-related complications: regimen-related toxicity (number of patients) 0  I  II  III  IV   Pulmonary  37  3  3  1  0  Cardiac  36  5  2  1  0  Hepatic  36  7  1  0  0  Renal  36  5  2  1  0  Stomatitis  35  3  3  3  0  Gastrointestinal  39  3  1  1  0  Bladder  42  1  1  0  0 gastrointestinal toxicity. No grade IV non-hematological organ toxicity was observed.
Bearman score
Engraftment
Five patients could not be evaluated for engraftment due to early death, prior to engraftment. The cause of death in these five patients was refractory sepsis in three, early relapse in one and central nervous system bleeding in one patient. Thirty-five of the remaining 39 patients demonstrated sustained engraftment, as defined by neutrophil counts above 0.5 ϫ 10 9 /l and an unmaintained platelet count of Ͼ20 ϫ 10 9 /l for at least 3 consecutive days. Absolute neutropenia lasted from 4 to 12 days. Four patients had no engraftment at all and reconstituted with leukemic cells. The median time to reach an absolute neutrophil count of 0.5 ϫ 10 9 /l was 16 days (range 7-29 days) (Figure 1b) . The median time to achieve platelet engraftment was 13 days (range 10-32 days). There was no significant difference in neutrophil engraftment with regard to the three different preparative regimens. However, platelet engraftment was faster in the group of patients treated with Bu/Flu in comparison to the Bu/Flu/ATG preparative regimen (P = 0.01; t-test). There was no significant difference with regard to engraftment in MRD in comparison to MUD transplant patients. Thirty-five patients who demonstrated sustained engraftment revealed stable donor chimerism. Figure 2a shows the mean values of donor chimerism with standard deviations on days +30, +60 and +100 for patients with sustained engraftment. There was no significant difference in chimerism with regard to the three different preparative regimens (Figure 2b) . Thirty-five patients who demonstrated sustained engraftment revealed stable donor chimerism.
Graft-versus-host disease
Out of 39 patients available for the assessment of GVHD, 14 (36%) developed grade III-IV acute GVHD. Four of these 14 patients died as a consequence of severe GVHD and in three of them persistent leukemia also contributed to the death. Eleven patients (28%) developed grade I to II acute GVHD. Twenty-five patients were assessed for chronic GVHD; 19 patients (76%) developed cGVHD. There was no significant difference with regard to GVHD incidence in MRD in comparison to MUD transplant patients. However, a trend to more severe GVHD after a MUD was noted in comparison to the MRD transplants (median grade of GVHD 1.57 vs 1.13). 
CMV infections
Early CMV reactivation was monitored by using CMV-PCR. Eleven out of 39 (28%) experienced CMV infection. Two of the 11 patients had no GVHD, but died on day +53 and day +32 due to AML progression. All patients with CMV infections were treated with ganciclovir at a standard dose of 5 mg/kg/BW twice daily for 14 days. In cases of severe myelotoxicity due to ganciclovir therapy or CMV refractoriness, therapy was changed to foscarnet.
Disease response, relapse and survival
Disease status is depicted in Table 1 . It should be noted that in the group of patients with AML, four were in CR and 22 had refractory disease, one patient was untreated. 
Survival analysis
The median follow-up of patients (ie those surviving day 50) was 18.5 months. Kaplan-Meier estimated probability of event-free and overall survival was 43%. However, the estimated EFS at 12 months for patients with good risk disease prior to transplant (CR, CP and patients with CLL) was 75%, while for patients with high risk (PR, refractory disease, >CP) the estimated EFS at 12 months was 25% (Figure 3a ; P Ͻ 0.05). In addition, the estimated EFS at 12 months for patients after MRD transplantation was significantly higher in comparison to MUD/PMUD and PMRD (69% vs 29%; P Ͻ 0.05, Figure 3b ). We also analyzed transplant influence with regard to TRM, engraftment and incidence of GVHD. There was no significant difference with regard to TRM and engraftment with MRD compared to MUD transplants, although a trend towards worse GVHD was found in MUD as compared to MRD transplants. In addition, influence of age on TRM was not significant. There was no significant difference in EFS and OS (Figure 4 ) or in incidence of GVHD and TRM with regard to the different preparative regimens used in the study.
Discussion
The aims of myeloablative preparative regimens are to provide tumor cytoreduction and ideally disease eradication, and to enable immunosuppression to overcome host rejection of donor stem cells. [19] [20] [21] However, there is increasing evidence that stable donor chimerism can be achieved with recently developed dose-reduced preparative regimens. [1] [2] [3] 22 Dose-reduced preparative regimens have usually been based on the purine analogue, fludarabine and have facilitated allogeneic engraftment while limiting regimen-related mortality. However, a high incidence of acute GVHD (from 40 to 60%) has been the leading cause of death in these patients. [1] [2] [3] 8 In our study, three different dose-reduced preparative regimens were compared in a group of 44 patients with hematological malignancies. We did not observe any differences between patients treated with the different dosereduced preparative regimens, with regard to disease stage and diagnosis. In addition, no difference was found between patients treated with the different dose-reduced preparative regimens with regard to incidence of engraftment, chimerism, toxicity, TRM, GVHD and survival. An allogeneic nonmyeloablative stem cell transplantation protocol has been published by Giralt et al, 1 Slavin et al, 2 Khouri et al 3 and recently by McSweeney et al.
22
The original Slavin protocol consisted of fludarabine, busulfan and ATG. ATG was used in order to intensify recipient immunosuppression and to ensure engraftment. Indeed, no graft failures were reported in the 26 patients treated with this combination. Recently, Bornhäuser et al 8 reported durable engraftment using less fludarabine without ATG in patients with advanced leukemia, lymphoma or solid tumors, receiving PBSC from HLA-matched sibling donors. Therefore, the role of ATG for engraftment in HSCT remains undefined. A randomized study comparing the outcome of patients treated with and without ATG during the preparative regimen is needed in order to answer this question. The preparative regimen published by Khouri et al 3 consisted of fludarabine and cyclophosphamide in patients with CLL and lymphoma. The results indicated the feasibility of using this nonmyeloablative preparative regimen to ensure engraftment and GVL against lymphoid malignancies. A similar preparative regimen was used by Carella et al 23, 24 in patients with Hodgkin's lymphoma, NHL and advanced stage CML. A fludarabine-melphalan conditioning regimen has been used at the MD Anderson Cancer Center as a more intense, but still nonmyeloablative regimen for patients considered poor candidates for the conventional preparative regimen. Eighty-six patients with a variety of hematological malignancies were treated with this regimen. 25 The use of low dose (2 Gy) TBI recently published by McSweeney et al 22 showed that the regimen was safe and minimally toxic in a heterogenous group of 44 patients with hematologic malignancy. In addition it has been shown that 53% of patients with sustained engraftment were in complete remission with an estimated survival of 66.7% and non-relapse mortality of only 6.7% (median follow-up: 417 days). Reduced organ toxicity and non-relapse mortality using a low-dose TBI-based (5.5 Gy) preparative regimen in a cohort of patients with CML has been recently published. 26 The Kaplan-Meier estimate of survival at 2 years was 83% in this study.
The second major point in our study is the high number of patients with AML treated with a dose-reduced preparative regimen. Most of these patients were refractory to previous chemotherapy. Seventeen percent of them are longterm survivors, indicating that by using nonmyeloablative preparative regimens, HSCT might be offered to selected patients with refractory AML. According to our experience, patients with a hypocellular marrow containing blasts may benefit from such a treatment. The long-term antitumor activity of this regimen remains unknown and longer follow-up is needed. In a recent review article summarizing the results of low intensity regimens in three transplant centers, Genoa, Jerusalem and Houston, 25 34 patients were diagnosed with AML, but no further details with regard to disease status or outcome were given. 
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In our study, the incidence of acute GVHD grade II-IV (56%) was similar to the data previously reported (Table 4) . [1] [2] [3] [4] 8, 22, [27] [28] [29] In order to reduce the incidence of GVHD, which contributes to morbidity and mortality after HSCT, Kottaridis et al 30 developed a novel nonmyeloablative regimen for allogeneic HSCT, designed to suppress the recipient immune system by adding CAMPATH-1H to the preparative regimen. In this study, there were no cases of grade III or IV acute GVHD, while grade II GVHD occurred in only two out of 44 patients and one patient developed chronic GVHD. Although interesting, it should be noted that this approach could have some disadvantages with regard to GVL effect. 31 Seven patients relapsed or progressed following transplantation, indicating the absence of the well-known anti-leukemic activity associated with clinically evident GVHD. 30 The alternative approach in older patients could be conditioning with an intensified regimen followed by T-cell-depleted BMT as recently reported. 32 Our chimerism data demonstrate that patients engrafted with predominantly donor hematopoiesis. However, we observed a significant incidence of mixed chimerism, defined as more than 2.5% of recipient cells in the first 30 days after transplantation and at follow-up, similar to the published data. 1, 2, 8 CMV infection is the most common viral infection and one of the major causes of morbidity and mortality after HSCT. With pre-emptive strategies and myeloablative preparative regimens, an incidence of CMV infection ranged from 23 to 86%. [33] [34] [35] The incidence of CMV infection after nonmyeloablative preparative regimens has not been studied in a large number of patients. The recent data published by Mohty et al 36 indicate that early CMV infection occurred in 65% of the patients treated with a nonmyeloablative preparative regimen for high risk hematological malignancies. In contrast to these findings, the incidence of CMV infection was lower in our patients (28%). One explanation could be that all donor-recipient pairs were CMVseropositive prior to transplantation in the study of Mohty et al, 36 while the donor-recipient pairs in our study were positive in 75% of patients.
In conclusion, our original preparative regimen, 4 Gy TBI and fludarabine, is well tolerated, safe and feasible. Survival was significantly better in MRD transplant patients in comparison to MUD patients, thus indicating that patients with an HLA-identical sibling donor have the best chances with this approach. This approach might be of benefit in a carefully selected patient population diagnosed with refractory AML and also in some patients with ALL. Moreover, our data for patients with CML and CLL are encouraging, although the number of patients is still small. However, there are some limitations to our study: the follow-up period of 18.5 months although longer in comparison to other studies (Table 4) , is still short and the patients remain at risk of relapse. The number of patients is relatively small, indicating that further studies with more patients and longer follow-up are needed in order to assess more adequately the role of dose-reduced regimens in the treatment of hematological malignancies.
